Cyramza 500 MG/50 ML vial 50ML
Ended Awarded Last action
- Contract number
- SPE2DR26FFBT9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $22,091
Award facts
- Contract value 100% obligated
- $22,090.68 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $22,090.68 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Cyramza 500 mg/50 mL vials. The contract, awarded on January 2, 2026, with an ultimate completion date of January 26, 2026, is structured as a firm fixed-price delivery order with no set-aside designation. This award was issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which carries a $499.9 billion ceiling and extends through December 31, 2036.
DMS Pharmaceutical Group serves as a critical pharmaceutical supplier to the Department of Defense medical supply chain, with demonstrated expertise in distributing oncology treatments, biologics, vaccines, and specialty pharmaceuticals to military healthcare facilities. The company's single-award IDC under the PPV-G GEN V program positions it as one of multiple regional prime vendors within the broader $30.3 billion acquisition strategy, enabling the Defense Logistics Agency to issue delivery orders for the comprehensive range of pharmaceutical products required to support military medical operations globally. This specific delivery order for Cyramza, an oncology therapeutic, reflects the company's ongoing role in fulfilling specialized pharmaceutical requirements for federal military healthcare.
Quick answers
Who was awarded contract SPE2DR26FFBT9?
SPE2DR26FFBT9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 2, 2026.
How much is contract SPE2DR26FFBT9 worth?
The government has obligated $22,091 on SPE2DR26FFBT9.
Is contract SPE2DR26FFBT9 an order under another contract?
Yes. SPE2DR26FFBT9 is a delivery order under SPE2DR25D9239, an indefinite delivery contract.
Was contract SPE2DR26FFBT9 competed?
The extent of competition for SPE2DR26FFBT9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award